The collective data from these phenotypic screens indicate that inhibitors of epidermal growth factor receptors (EGFRs) and erythroblastic leukaemia viral oncogene homologues (ErbBs) represent a group of compounds that are most effective against chordoma cell growth in vitro in the absence of common driver mutations in EGFRs and their downstream effectors [9–12]. The gene discussed is EGFR; the disease is chordoma.